Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07579845

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Detoxification Biological Aging Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

OvationLab

Richmond, Virginia, 23220, United States

Location status: Recruiting

Location contact

Study Administration

CONTACT

[email protected]

‪(240) 232-2103‬

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult females or males age ≥ 40 years
  • Ability to read and speak English

Exclusion criteria

  • Current use of a dietary supplement containing fulvic or humic acid
  • Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
  • Known allergies to any ingredients in the product
  • Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
  • Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
  • Participants unable to provide consent

Treatment and study plan

Humic and Fulvic Acid Dietary Supplement

Dietary Supplement

BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement

Primary outcomes

  1. TruDiagnostic - Epigenetic Testing

    Time frame: Change in TruAge from baseline to 12 weeks

    TruAge Test

Study contacts

Contact information is provided by the study sponsor or research team.

Study Administrator

CONTACT

[email protected]

(240) 232-2103

Sponsors and collaborators

Lead sponsor

OvationLab

Network

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 12, 2026
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.